⏱️34 min read | As we usher in 2026, we look back on the landmark clinical trial findings, advancements in research, regulatory disappointments, and thunderous community unity that will define 2025 for the Huntington’s disease community.

Scientists engineered stem cells with "interrupted" CAG repeats to break up the toxic stretch. This may stop expansion, and could improve problems in cells that model Huntington’s disease. This study suggests that DNA spelling can drive the disease.

POINT-HD has begun dosing its first participants with the drug RG6496, marking an early but important step for a new selective huntingtin-lowering approach.